{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T19:50:45Z","timestamp":1754164245571,"version":"3.41.2"},"reference-count":5,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Dermatol Surg","DS"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1097\/dss.0000000000002189","type":"journal-article","created":{"date-parts":[[2019,9,30]],"date-time":"2019-09-30T23:56:12Z","timestamp":1569887772000},"page":"132-133","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Future Directions and Challenges Facing Intralesional Immunotherapy With Talimogene Laherparepvec for Advanced Melanoma"],"prefix":"10.1097","volume":"47","author":[{"given":"Dawn","family":"Queen","sequence":"first","affiliation":[{"name":"Columbia University Vagelos College of Physicians and Surgeons, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faramarz H.","family":"Samie","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Columbia University Irving Medical Center, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie C.","family":"Zeitouni","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Arizona COM Phoenix, Phoenix, Arizona"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"issue":"Suppl","key":"R1-20250731","doi-asserted-by":"crossref","first-page":"LBA9008","DOI":"10.1200\/jco.2013.31.18_suppl.lba9008","article-title":"OPTiM: a randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB\/C and IV melanoma","volume":"31","author":"Andtbacka","year":"2013","journal-title":"J Clin Oncol"},{"key":"R2-20250731","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1200\/JCO.2017.73.7379","article-title":"Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma","volume":"36","author":"Chesney","year":"2018","journal-title":"J Clin Oncol"},{"key":"R3-20250731","doi-asserted-by":"crossref","first-page":"S202","DOI":"10.1016\/j.jid.2018.03.1207","article-title":"Distinguishing melanophages from melanoma in metastatic melanoma treated with T-VEC: a clinical application of quantitative multiplex immunofluorescence","volume":"138","author":"Bayan","year":"2018","journal-title":"J Investig Dermatol"},{"key":"R4-20250731","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1097\/CJI.0000000000000265","article-title":"Response to the rechallenge with talimogene laherparepvec","volume":"42","author":"Afzal","year":"2019","journal-title":"J Immunother"},{"key":"R5-20250731","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s40425-018-0338-6","article-title":"Complete intracranial response to talimogene laherparepvec (T-Vec), pembrolizumab and whole brain radiotherapy in a patient with melanoma brain metastases refractory to dual checkpoint-inhibition","volume":"6","author":"Blake","year":"2018","journal-title":"J Immunother Cancer"}],"container-title":["Dermatologic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/DSS.0000000000002189","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T22:12:23Z","timestamp":1753999943000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/DSS.0000000000002189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":5,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/dss.0000000000002189","relation":{},"ISSN":["1076-0512","1524-4725"],"issn-type":[{"type":"print","value":"1076-0512"},{"type":"electronic","value":"1524-4725"}],"subject":[],"published":{"date-parts":[[2021,1]]}}}